Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dequalinium Chloride and Clindamycin for Bacterial Vaginosis
NCT04067531Phase 3Unknown
- Sponsor
- Skaraborgs sjukhus
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dequalinium in bacterial vaginosis (BV), sponsored by Skaraborgs sjukhus. Primary endpoint: Cure of bacterial vaginosis at 6 months. Status: unknown.
02
Drugs
dequalinium
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT04067531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067531.